New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
16:49 EDTXNPTXenoPort entitled to $20M upfront payment on license pact
In a regulatory filing, XenoPort disclosed that as previously reported, on May 14, XenoPort (XNPT) entered into an exclusive license agreement with Reckitt Benckiser Pharmaceuticals. Pursuant to the terms of the License Agreement, upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act, as amended, which clearance was obtained on June 19, the company granted to Reckitt exclusive, world-wide rights to develop and commercialize pharmaceutical products containing arbaclofen placarbil and other prodrugs of baclofen or R-baclofen for all indications, subject to the company’s right of first negotiation with Reckitt to collaborate to develop and commercialize Products for non-addiction indications. In exchange for these rights under the License Agreement, the company is entitled to receive an upfront, non-refundable cash payment of $20M and is entitled to receive an additional $5M after delivery of certain technology and materials. The company is also eligible to receive aggregate cash payments of up to $120M upon the achievement of certain predefined milestones, of which $70M are regulatory and development-based milestones and $50Mn are commercialization-based milestones. In addition, the company is entitled to receive tiered double-digit royalty payments of up to the mid-teens on a percentage basis on potential future net sales of the Products in the U.S., and high single-digit royalty payments on potential future net sales of the Products outside the U.S. In addition, the company will transfer its existing arbaclofen placarbil investigational new drug applications, INDs, know-how and other related data to Reckitt, and the company will provide technology transfer assistance to Reckitt to facilitate the establishment of Reckitt’s manufacturing and supply capabilities pursuant to a transition plan to be mutually agreed upon.
News For XNPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 11, 2015
15:05 EDTXNPTXenoPort believes FDA accepeted NIAAA design for Horizant trial
Subscribe for More Information
15:04 EDTXNPTXenoPort says Horizant 13-week prescriptions increased 18%
XenoPort reported an update on prescription trends and further development of Horizant Extended-Release Tablets, including feedback from the FDA on development for treatment of alcohol use disorder. Horizant prescription trend highlights include: The number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the prior 13 weeks ending September 19, 2014 and an increase of 95% over the 13-week period ending December 20, 2013. The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742. The current wholesale acquisition cost price is $7.69 per tablet. During Q3, XenoPort increased its field sales force of NeuroHealth Sales Specialists from approximately 40 to 65 representatives. The number of prescribed tablets for the 13 weeks ending December 19, 2014 in the territories occupied by the new NHS Specialists was 227,897, an increase of 46% compared to the 13 weeks ending June 27, 2014, which was prior to the addition of the new NHS Specialists.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use